Hirokazu Sasaki¹, Shigeru Kusumoto¹, Ayako Masaki², Haruna Fujinami¹, Yoshiko Ohshima¹, Takuto Tachita¹, Yoshiaki Marumo¹, Takashi Yoshida¹, Tomoko Narita¹, Asahi Ito¹, Masaki Ri¹, Hirokazu Komatsu¹, Hiroshi Inagaki², Shinsuke Iida¹ (1.Hematology and Oncology, Nagoya City University, Nagoya, Japan., 2.Anatomic Pathology and Molecular Diagnosis, Nagoya City University, Nagoya, Japan.)

Yukari Shirasugi¹, Wataru Munakata², Kiyoshi Ando¹, Shinichi Makita², Makoto Onizuka¹, Dai Maruyama², Rikio Suzuki¹, Koji Izutsu², Hidetsugu Kawai¹, Tadashi Nakanishi³, Sari Shiba⁴, Kensei Tobinai² (1.Haematology and Oncology, Tokai University School of Medicine, Isehara, Japan, 2.Department of Hematology, National Cancer Hospital, Tokyo, Japan, 3.Department of Clinical Development, Eisai Co., Ltd., Tokyo, Japan, 4.Department of Clinical Pharmacology, Eisai Co., Ltd., Tokyo, Japan)

Toshiki Uchida¹, Kensei Tobinai², Noriko Fukuhara³, Wataru Munakata², Shinichi Makita², Miki Kobayashi¹, Shigeki Saito¹, Yohei Yamaguchi¹, Tomoaki Nishikawa⁴ (1.Japanese Red Cross Nagoya Daini Hosp., Nagoya, Japan, 2.National Cancer Ctr. Hosp., Tokyo, Japan, 3.Tohoku Univ. Hosp., Sendai, Japan, 4.Janssen Pharmaceutical K.K., Tokyo, Japan)

Noriko Fukuhara¹, Hirokazu Nagai², Dai Maruyama³, Toshiyuki Kitano⁴, Takayuki Ishikawa⁵, Hirohiko Shibayama⁶, Ilseung Choi⁷, Kiyohiko Hatake⁸, Toshiki Uchida⁹, Momoko Nishikori⁴, Tomohiro Kinoshita¹⁰, Yoshihiro Matsuno¹¹, Tomoaki Nishikawa¹², Kensei Tobinai³ (1.Tohoku Univ. Hosp., Sendai, Japan, 2.NHO Nagoya Med. Ctr., Nagoya, Japan, 3.National Cancer Ctr. Hosp., Tokyo, Japan, 4.Kyoto Univ. Grad. Sch. Med., Kyoto, Japan, 5.Kobe City Med. Ctr. General Hosp., Kobe, Japan, 6.Osaka Univ. Grad. Schl. Med., Osaka, Japan, 7.NHO Kyusyu Cancer Ctr., Fukuoka, Japan, 8.The Cancer Institute Hosp. JFCR, Tokyo, Japan, 9.Japanese Red Cross Nagoya Daini Hosp., Nagoya, Japan, 10.Aichi Cancer Ctr., Nagoya, Japan, 11.Hokkaido Univ. Hosp., Sapporo, Japan, 12.Janssen Pharmaceutical K.K., Tokyo, Japan)

Noriko Fukuhara¹, Dai Maruyama², Kiyohiko Hatake³, Hirokazu Nagai⁴, Kenjiro Kamezaki⁵, Saori Kosaka⁶, Kensei Tobinai² (1.Hematology and Rheumatology, Tohoku Univ., Sendai, Japan, 2.Hematol., National Cancer Cent., Tokyo, Japan, 3.Cancer Inst. Hosp., Japanese Found. for Cancer Res., Tokyo, Japan, 4.Hematol., National Hosp. Nagoya Med. Cencer, Nagoya, Japan, 5.Cellular and Molecular Med., Kyushu Univ., Fukuoka, Japan, 6.Bayer Yakuhin, Ltd., Osaka, Japan)

Tomoko Yanai¹, Koji Izutsu^2,3, Michinori Ogura⁴, Kensei Tobinai², Kiyohiko Hatake⁵, Shigeru Sakamoto¹, Yasuhiro Katsura⁶, Masanori Nishimura⁶, Mikiko Hashimoto¹ (1.Japan Medical Affairs, Takeda Pharmaceutical Co. Ltd., Tokyo, Japan, 2.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 3.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 4.Department of Hematology/Oncology, Kasugai Municipal Hospital, Kasugai, Japan, 5.Department of Hematology and Oncology, Cancer Institute Hospital, Tokyo, Japan, 6.Pharmacovigilance, Takeda Pharmaceutical Co. Ltd., Osaka, Japan)